Author: Staff Writer

  • Confusion Continues to Cloud Proposed Nicotine Tax

    Confusion Continues to Cloud Proposed Nicotine Tax

    Credit: Leo Lintang

    Experts say Congress’ latest attempt to tax nicotine is complicated, confusing and harmful to public health.

    By Timothy S. Donahue          

    To help pay for an infrastructure bill, the U.S. Congress has again introduced an excise tax on next-generation nicotine products, such as e-cigarettes and snus. The excise tax would apply to nicotine vapor products using both natural and synthetic nicotine as well as nicotine pouches. Experts say the provision, which would ultimately be paid by tobacco consumers, goes against U.S. President Biden’s campaign promise to not increase taxes on those making less than $400,000, negatively impact tobacco harm reduction efforts, increase sales of combustible tobacco products and boost an already growing black market.

    The nicotine tax has been removed and reintroduced to Biden’s Build Back Better (BBB) legislation at least three times. The proposed vapor tax provision is now part of the latest version of the administration’s social spending and climate bill. According to Ulrik Boesen, a senior policy analyst with the Center for State Tax Policy at the Tax Foundation, taxes on tobacco and nicotine products tend to serve at least two purposes: to improve public health and raise revenue. He claims that a nicotine tax could do that if it is properly designed.

    Ulrik Boesen / Credit: Tax Foundation

    “A good design means internalizing externalities related to consumption of a product,” Boesen stated. “With tobacco and nicotine product consumption, these externalities are the health risks connected to frequent use and [the] quantity consumed. Nicotine is the addictive substance in the products but not the harmful ingredient. In other words, the proposal does not target the harmful behavior directly.”

    Taxing based on nicotine content would favor low-nicotine liquids and could encourage increased consumption in the quantity of liquid, according to Boesen. “For example, a vapor pod that has a nicotine content of 3 percent and contains 1 mL of liquid would be taxed at $0.83 whereas a vapor pod that has a nicotine content of 5 percent and also contains 1 mL of liquid would be taxed at $1.39 even if there is no difference, or even a negative differential, in broader health effects of the two pods,” he states, adding that the effects of the tax are most substantial for nicotine pouches, such that the category is unlikely to survive.

    Other estimates show that a 60 mL bottle of e-liquid with 12 mg of nicotine e-liquid would be taxed at $20.02. A four-pack of 8 mL pods with 5 percent nicotine salt pods would be taxed at $4.45 and a 15-pouch can of 8 mg nicotine pouches would be taxed at $3.34 (alongside state and local taxes, the cost of a single can could grow to $20 in some states).

    Bryan Haynes, a partner with the law firm Troutman Pepper who specializes in tobacco and vapor regulations, said that, at a minimum, the proposed nicotine tax is “a hastily written addition” that will “have a negative impact on tobacco harm reduction efforts and public health.” He said that it’s the first time the tobacco industry has seen an excise tax placed on an ingredient instead of a finished good. “This is an unprecedented type of tax that will ultimately drive former smokers back to combustible products,” said Haynes, adding that taxing an ingredient could also cause unforeseen issues for manufacturers, such as moving material between factories.

    Bryan M. Haynes
    Bryan Haynes / Credit: Troutman Pepper

    “If a company is producing nicotine or even synthetic nicotine, moving product from one factory to another could trigger the need for an Alcohol and Tobacco Tax and Trade Bureau (TTB) license, and when product is removed, so to speak, from their factory, they would be responsible for remitting the taxes,” explained Haynes. “There may be a way, for example, if the company removed the nicotine from their factory and transported it in-bond to another TTB factory that you could make that work. But it’s just not clear. There is the potential for a lot of unforeseen issues to arise the way the tax is currently being proposed.”

    States often tax nicotine products by its cost. Boesen says the tax on the product will pyramid since the federal tax would be levied at the manufacturer level and the state tax is levied at the distribution level. “In effect, the state tax base includes the federal tax and becomes a tax on a tax. This means that even if the taxes on tobacco and other nicotine products are approximately equal at the federal level, by the time it reaches the consumer, the nicotine product will carry a higher tax (and often a higher price),” he states. “This is highly problematic when considering that cigarettes are much more harmful than nicotine products. That makes the federal tax proposal look like a harm-maximizing strategy.”

    Credit: Tax Foundation

    The bill also subjects synthetic nicotine products to the nicotine tax. Many in the industry have expressed concern that this provision could allow the U.S. Food and Drug Administration to assert authority over the substance. Synthetic nicotine is covered not only in the proposed tax bill but also in the Prevent All Cigarette Trafficking (PACT) Act, which bans the U.S. Postal Service from mailing any vaping products.

    Azim Chowdhury, a partner at the law firm Keller and Heckman who specializes in vapor, nicotine and tobacco product regulation, said that’s just not possible and Haynes agrees. “The definition of a tobacco product in the Tobacco Control Act (TCA) is clear. It’s just not ambiguous; a product must be made or derived from tobacco, or a component or part of a tobacco product, to be a tobacco product,” said Chowdhury. 

    azim-chowdhury
    Azim Chowdhury

    “Congress would have to change the Tobacco Control Act’s definition of a tobacco product in order to give FDA’s Center for Tobacco Products the authority to regulate synthetic nicotine products as tobacco products. That won’t happen overnight. I also see a scenario where synthetic nicotine could be regulated as a drug and that would be a whole different and more onerous regulatory regime.”

    The FDA could, however, cite the inclusion of synthetic products in the PACT Act and the latest nicotine tax proposal in its lobbying efforts to change the TCA’s definition of tobacco, said Haynes. “I could see the FDA telling Congress, ‘You just amended the Internal Revenue Code to make these products subject to federal excise taxes just like tobacco-derived nicotine, so it’s not a big stretch to amend the Tobacco Control Act’ in the same way,” he explains. “That’s how I would do it. It’s not really a legal argument, but it could be a decent lobbying argument.”

    It isn’t just vapers, business owners and attorneys that find fault with the proposed nicotine tax; researchers suggest the tax could also harm public health. Michael Pesko, an associate professor in the Department of Economics at Georgia State University, used a $1.4 million dollar grant from the National Institutes of Health (NIH) to conduct e-cigarette policy evaluation research, including the evaluation of e-cigarette taxes (Pesko receives no funding from the tobacco industry or related groups). Pesko found that e-cigarettes and other nicotine vaping products function as what economists call “substitutes” for conventional cigarettes.

    “In practical terms, if e-cigarettes and cigarettes are substitutes, then raising the price of one on average leads people to increase use of the other. Given extensive peer-reviewed evidence indicating that these products are substitutes, an unintended but inevitable effect of increasing taxes on e-cigarettes is to increase cigarette use,” Pesko said. “Given that cigarettes are believed to be substantially more harmful than e-cigarettes, this effect on [combustible] cigarette use is concerning …. A wide array of research suggests that this boost in cigarette use as a result of large e-cigarette tax increases would significantly increase overall tobacco-related death and disease.”

    Michael Pesko / Credit: GSU

    These findings prompted Pesko to send a letter to Congress concerning the proposed vape tax. In the letter, he states that his research team’s economic evaluations of existing state and county e-cigarettes taxes found that increasing e-cigarette taxes to parity with the combustible cigarette tax rate would “sizably increase cigarette use across teens, adults and pregnant women compared to taxing tobacco products differentially in proportion to their health risk.”

    Pesko said researchers found several concerning consequences of large e-cigarette tax increases:

    • Simulating the current bill’s e-cigarette tax on teen tobacco use indicates that this policy would reduce teen e-cigarette use by 2.7 percentage points but that two in three teens who do not use e-cigarettes due to the tax would smoke cigarettes instead. This would result in approximately a half million extra teenage smokers overall. This finding that teens substitute to cigarettes in response to e-cigarette taxes has also been documented using National Youth Tobacco Survey data.
    • The tax would raise the number of daily adult cigarette smokers by 2.5 million nationally and reduce adult e-cigarette users by a similar number.
    • For every e-cigarette pod eliminated by an e-cigarette tax, more than 5.5 extra packs of cigarettes are sold instead.
    • For every three pregnant women that do not use e-cigarettes due to an e-cigarette tax, one smokes cigarettes instead (study).

    Pesko told Vapor Voice he was surprised to find that increased e-cigarette tax consistently resulted in substitution across various data sources. “And the magnitudes are fairly sizable,” he noted. “This is an unusual level of accordance for academic research.” Pesko believes that any tax on nicotine products should be based on quantity.

    Boesen agreed. He stated that for vapor products, the “obvious choice” is taxing the liquid by volume (per mL), and for nicotine pouches, a tax by weight or per pouch is a straightforward solution. “It is the administratively simplest and most straightforward way for the federal government to tax these goods as it does not require valuation and as such does not require expensive administration,” he stated. “The nicotine tax proposal in the Build Back Better Act neglects sound excise tax policy design and by doing so risks harming public health. Lawmakers should reconsider this approach to nicotine taxation.”

    Chowdhury said that the industry must do more and that interested stakeholders and consumers should reach out and push back on the nicotine tax because it will be devastating to the vapor industry. “It seems like the general industry feels like [this nicotine tax] won’t get through somehow, that some people will prevent it from being in the final bill, but I think it’s a huge risk,” said Chowdhury. “Without serious pushback, it could end up there; it could very well end up becoming law.”

    Haynes said that if the nicotine tax bill ever makes it to Biden’s desk, “he’s going to sign it.”

  • Reynold’s Settles Vuse Patent Suit Days Before Trial Starts

    Reynold’s Settles Vuse Patent Suit Days Before Trial Starts

    R.J. Reynolds (RJR) has settled an e-cigarette manufacturer’s claims that Reynold’s Vuse products infringed on the manufacturer’s e-cigarette patents. RJR, a BAT subsidiary, settled the suit just four days before the trial was slated to begin, according to a Thursday filing in North Carolina federal court.

    Credit: MD3D

    U.S. District Judge Catherine Eagles found in May that RJR’s products infringed parts of two Fuma International’s patents. A jury in Greensboro, N.C., was set to consider on Monday whether RJR infringed additional parts of one of the patents, whether the patents were valid, and what damages RJR owed, among other things, according to Reuters.

    Fuma sued Winston-Salem, N.C.-based RJR in 2019 for infringing patents related to an e-cigarette design with a cartridge and power source. The complaint said RJR copied Medina, Ohio-based Fuma’s design after meeting with Fuma about its e-cigarette technology in 2010.

    Fuma was asking for up to $135 million in damages, according to court filings.

    Vuse is one of the most popular e-cigarette brands in the country. RJR introduced the Vuse Solo in 2013 and the Vuse Ciro in 2017. The U.S. Food and Drug Administration gave RJR permission to market Solo in October, its first-ever authorization for a vaping product.

    The tobacco giant argued the relevant parts of the patents were invalid based on prior art that disclosed the same design, according to Reuters. Details of the settlement weren’t immediately available.

  • Biden Taps Ex-FDA Boss Califf To Lead Agency Again

    Biden Taps Ex-FDA Boss Califf To Lead Agency Again

    Robert Califf

    U.S. President Joe Biden today announced that he would nominate Robert M. Califf, a former commissioner of the Food and Drug Administration, to lead the agency again, reports The New York Times.

    A cardiologist and long-time consultant to drug companies, Califf ran the FDA during the last year of the Obama administration

    “Dr. Califf is one of the most experienced clinical trialists in the country, and has the experience and expertise to lead the Food and Drug Administration during a critical time in our nation’s fight to put an end to the coronavirus pandemic,” Biden said in a statement.

    Califf has been a forceful advocate for tobacco control; before he was the FDA commissioner, he was the agency’s deputy commissioner for medical products and tobacco. In an appearance with other former commissioners this year, he said, “I have never seen more capable or nastier lawyers than what I experienced in trying to deal with the tobacco industry. It was awesome and quite frightening for public health.”

    After stepping down as the vice chancellor for clinical and translational health at Duke University, Califf has worked as a senior adviser to Verily Life Sciences, a health technology firm, and its sister company Google Health. Califf, who remains an adjunct professor of medicine at both Duke and Stanford University, is on the corporate board of Cytokinetics, a biopharmaceutical company, according to its website.

    Califf said he was honored to be nominated for the position “at a critical time for our country,” adding, “There’s a lot of work to do, and if confirmed I look forward to rejoining the great team at the FDA to help in their inspiring mission to serve the public.”

    The FDA has had seven different commissioners, including Califf, since 2012, when Margaret Hamburg left the post.

  • Free Tobacco Tax Seminar Starts at 2pm Eastern Time

    Free Tobacco Tax Seminar Starts at 2pm Eastern Time

    IGEN is offering a free tobacco tax seminar today at 2pm Eastern time.

    Tax on Top of Tax: Understanding Excise and Sales Tax for Tobacco Companies

    Thursday, November 11, 2021 at 02:00 PM Eastern Standard Time.

    Here is the registration link: https://event.on24.com/wcc/r/3503035/62668563942F38D446017F0BADE87F98

  • ‘Proposed Vapor Tax Would Lead to Millions More Smokers’

    ‘Proposed Vapor Tax Would Lead to Millions More Smokers’

    Photo: New Africa
    Guy Bentley

    The nicotine tax in the U.S. Build Back Better Plan bill will negatively affect public health and hurt lower- and middle-class Americans, according to Guy Bentley, director of consumer freedom research at the Reason Foundation.

    The current version of ever-changing proposal would introduce a new tax on e-cigarettes and other smoking alternatives, which research suggests are dramatically safer options for smokers.

    A 6 milligram nicotine/30 milliliter bottle of e-liquid, for example, would be taxed at a rate of $5.01 under the proposal. A typical pack of e-liquid pods would be taxed at $4.59. The federal tax on cigarettes is $1.01 per pack. Thus, e-cigarettes would be taxed more than regular cigarettes, and dramatically more so in states that already levy their own high e-cigarette taxes.

    Writing on the Reason Foundation’s website, Bentley cites Michael Pesko of Georgia State University, who estimates the new tax on nicotine alternatives would cause 2.7 million more daily adult smokers, 530,000 more teen smokers and 29,000 more prenatal smokers.

    This is because e-cigarettes are substitutes, not complements to combustible cigarettes, and millions of American ex-smokers have used these products to get off smoking traditional cigarettes.

    Bentley says the tax is also highly regressive and would violate President Biden’s campaign promise not to raise taxes on people earning less than $400,000 a year. According to a recent Gallup poll, Americans with an annual household income of less than $40,000 are significantly more likely to vape than higher-income groups.

    “With more than 15 million adult vapers now in America, many of whom attribute their ability to quit or reduce smoking traditional cigarettes to their use of e-cigarettes, it’s baffling House Democrats would consider targeting this group with a huge tax increase that could push many of them back to smoking and worsen public health,” wrote Bentley.

  • PMI Makes Case for U.S. Sales of IQOS at FDA

    PMI Makes Case for U.S. Sales of IQOS at FDA

    Credit: Aidman

    Philip Morris International met with the U.S. Food and Drug Administration on Nov. 5 to present its argument for why the multinational and Altria Group should be allowed to import and sell the IQOS tobacco-heating device in the U.S., reports CNBC.

    According to a CNBC source, PMI told the FDA that IQOS is unique in its ability to transition smokers away from combustible cigarettes, which the company says are more harmful to health than tobacco-heating devices.

    In late September, the International Trade Commission ruled that IQOS infringed on two of Reynolds’ patents. The Biden administration is conducting an administrative review until Nov. 29 to decide if the sale and import of the cigarette alternative will be banned.

    During the FDA meeting, PMI reportedly argued that the ITC overstepped its bounds, given that the FDA is in charge of regulating which tobacco products can be sold.

    The U.S. Trade Representative will make a recommendation to President Joe Biden after listening to input from a number of agencies, including the FDA, which regulates tobacco products.

    If the administration sides with R.J. Reynolds in the dispute, IQOS could be off of U.S. shelves for months as it waits for a decision on a separate claim from Reynolds with the U.S. Patent and Trademark Office.

    PMI has successfully defended similar cases in the U.K. and elsewhere. BAT has already pursued litigation over IQOS in Poland, the Czech Republic, Bulgaria, Romania and Greece and through the European Patent Office.

    In the worst-case scenario for Altria and Philip Morris, the two companies would have to go back to the drawing board, moving production to the U.S. or changing up the design enough to avoid patent infringement claims.

  • U.S. Lawmaker Scrutinizes Unregulated Synthetic Nicotine

    U.S. Lawmaker Scrutinizes Unregulated Synthetic Nicotine

    Raja Krishnamoorthi

    U.S. Representative Raja Krishnamoorthi, chair of the subcommittee on economic and consumer policy, has sent letters to two companies that manufacture or sell synthetic nicotine products, requesting information about the companies and their sale of these products.

    One letter was addressed to Next Generation Labs, the self-declared market leader in the production and sale of synthetic nicotine. The company claims its unregulated synthetic nicotine is used in more than 60 products and projects its sales to increase by 1,800 percent this year.

    Synthetic nicotine has been gaining popularity among vapor companies after the FDA denied hundreds of thousands of marketing applications for products made with conventional nicotine.

    “In response, some e-cigarette and e-liquid manufacturers, banned from legally selling their products, reportedly plan to switch to synthetic nicotine in an effort to avoid FDA regulation,” Krishnamoorthi wrote in his letter to Next Generation Labs.

    “Next Generation Labs appears to support this approach, with its co-founder, Ron Tully, offering the following thoughts on the FDA laws and regulations governing nicotine: ‘If the statute has been ill-conceived, and the regulation has been ill-drafted, it is not the responsibility of the industry to conform to some kind of idea that you can’t innovate in those spaces where the legislation doesn’t occur.’”

    Krishnamoorthi also sent a letter to Puff Bar, whose products have replaced Juul as the vape of choice for many young people after Juul Labs discontinued certain flavored products. In 2020, the Food and Drug Administration ordered Puff Bar to pull its products from the market. Earlier this year, the company introduced new versions of its products using synthetic nicotine.

    In a recent profile by The Wall Street Journal, Puff Bar co-CEO Patrick Beltran described the Puff Bar ingredient change as “a forced innovation,” saying that the FDA gave the company no choice. Because the Tobacco Control Act specifically gives the FDA authority to regulate nicotine “made or derived from tobacco,” most people believe the agency’s Center for Tobacco Products cannot regulate products that use synthetic nicotine—at least not without serious legal challenges, according to Vaping360.

    “You have apparently made the vile decision to continue enriching yourselves by poisoning children,” Krishnamoorthi wrote in his letter to Puff Bar. “Puff Bar’s meteoric rise in popularity among kids resulted in $156 million in sales in 2020 alone. Puff Bar should not be allowed to continue harming children due to FDA’s failure to regulate synthetic nicotine, and I intend to put an end to your predatory practices.”

    In his letter to Next Generation Labs, Krishnamoorthi requested information regarding the company’s sales and new business. In his letter to Puff Bar, Krishnamoorthi requested information regarding the company’s ownership and operations as well as support for the company’s assertion that it is using synthetic nicotine, and requested the company’s co-chief executive officers appear for transcribed interviews.

    Greg Conley, the president of the American Vaping Association, said Krishnamoorthi lacked evidence that the targets of his  investigation have broken any laws.  “As per the usual, he is playing politics, and we are hopeful the demands specified in his letter will be resisted,” Conley told Filter.

    “With youth vaping numbers and the associated moral panic continuing to decline,” he continued, “it remains to be seen whether Representative Krishnamoorthi’s primary goal—getting media attention focused on Representative Krishnamoorthi—will actually be met with this campaign.”

  • New Report Questions WHO’s Anti-Vaping Stance

    New Report Questions WHO’s Anti-Vaping Stance

    A new report, published today, raises major questions about the anti-vaping arguments and approach of the World Health Organization and billionaire philanthropist Michael Bloomberg.

    The WHO and Bloomberg have both made clear their opposition to safer nicotine alternatives despite growing evidence of lower harm and efficacy for smoking cessation.

    The WHO’s tobacco control program is funded in part by Bloomberg Philanthropies. In July of this year, the two parties restated their joint position at the launch of the WHO Report on the Global Tobacco Epidemic, 2021: Addressing New and Emerging Products. In this report, the WHO emphasized that electronic nicotine delivery systems are “a threat to tobacco control,” are harmful, and should be banned or highly regulated. Bloomberg, in his capacity as the WHO Global Ambassador for Noncommunicable Diseases and Injuries, and founder of Bloomberg Philanthropies, stated that tobacco companies are marketing new products such as e-cigarettes to “hook another generation on nicotine.”

    The International Network of Nicotine Consumer Organizations (INNCO) has now compiled a new dossier, titled, Bloomberg, WHO and the Vaping Misinfodemic, containing statements and evidence from healthcare experts, leading academics, politicians, respected journalists and research organizations that question the stance of the WHO and Bloomberg on safer nicotine alternatives to smoking and the relationship between the two parties.

    This dossier comes just a week after the U.K. Department of Health and Social Care announced that e-cigarettes could be prescribed on the National Health Service, a world first. That move by the U.K. government provoked significant public debate around the polar opposite views towards safer nicotine alternatives, such as vaping, held by the British government and the WHO.

    The dossier also comes as the Parties to the WHO Framework Convention on Tobacco Control convene to discuss tobacco and nicotine policy.

    The outcomes from COP9 discussions will determine how international tobacco control policies are implemented at a country level across the globe to address the fact that 1.1 billion people still smoke worldwide and 8 million die every year from tobacco-related diseases.

    The dossier highlights nine reasons why serious questions need to be raised about WHO and Bloomberg’s outright opposition to safer nicotine alternatives to deadly smoking. High on the list is their failure to distinguish between smoking addiction and nicotine dependence.

    They are shifting the harm focus from smoking to tobacco to nicotine—where it obviously doesn’t belong.

    “Effectively, through this failure they are shifting the harm focus from smoking to tobacco to nicotine—where it obviously doesn’t belong—nicotine does not cause cancer, heart or lung disease. Smoking does,” says Charles A Gardner, executive director at INNCO.

    This is backed up in the dossier by expert views on the profound difference between cigarette smoke and the drug, nicotine, including those expressed by Jamie Hartmann-Boyce, senior research fellow in health behaviors at the University of Oxford; Professor John Britton, emeritus professor of epidemiology University of Nottingham and special advisor to the Royal College of Physicians on Tobacco; Adam Afriye MP; and a joint statement by 15 past-Presidents of the world’s top professional society in the field of tobacco control, the Society for Research on Nicotine and Tobacco.

    The report also scrutinizes the WHO’s role in COP events, with evidence suggesting that it is very controlling in terms of the agenda and attendance. Unlike COP26, these tobacco control COP meetings are described as “all but excluding the media,” “well-known for the routine ejection of the public from proceedings,” and “notoriously secretive.”

    The dossier also reports on claims that only tobacco control nongovernmental organizations (NGOs) allowed to attend are those who subscribe to the WHO’s tobacco harm reduction denialist stance. The U.K. Parliament’s All-Party Parliamentary Group for Vaping recently issued a warning about the participation at COP9 of The Union, a major global NGO funded by Bloomberg Philanthropies.

    “The Union [International Union Against Tuberculosis and Lung Disease] recently issued a major report titled Where Bans are Best: Why Low- and Middle-Income Countries Must Prohibit E-cigarette and HTP Sales to Truly Tackle Tobacco. The Union is one of Bloomberg Philanthropies’ two top tobacco control grantees—the other is the U.S.-based Campaign for Tobacco-Free Kids,” says Gardner.

    “We are a good case in point. INNCO, which represents and supports the rights of 98 million adults worldwide, who use safer nicotine to avoid toxic forms of tobacco, has once again been denied Observer Status at COP9 (as it was denied at COP8, and at COP7).”

    The Bloomberg, WHO and the Vaping Misinfodemic report calls for:

    • Governments around the world to collectively challenge the WHO and Bloomberg’s current prohibitionist position on safer nicotine alternatives, and to demand to know why, in the face of 8 million tobacco-related deaths every year, the tobacco control field is the only field of public health that rejects harm reduction.
    • The formation of a global independent Tobacco Harm Reduction Working Group comprised of independent scientists, global health experts, specialist academics, and people who use safer nicotine (ex-smokers)
    • Withdrawal of funding from and/or boycott of future Conference Of Parties (COP) tobacco control meetings until the WHO considers the overwhelming evidence that safer nicotine alternatives such as vapes, snus, nicotine pouches and heat-not-burn help smokers quit, and save lives
    • Complete transparency in all tobacco control funding, grants and collaborations involving the WHO and Bloomberg
    • A full independent and international review into current and past tobacco control dialogue between Bloomberg Philanthropies, Bloomberg-funded NGOs and national governments in LMICs following allegations in the Philippines that the country’s Food & Drug Administration received funds from Bloomberg groups to support the implementation of the national tobacco control program
    • A complete review of the WHO’s public web-based Q&A on e-cigarettes, which has been described as “astonishingly bad”

    The dossier also spotlights the EVALI (e-cigarette, or vaping, product-associated lung injuries) crisis of 2019. The U.S.-only outbreak of lung injuries caused by bootleg THC (cannabinoid) vape oils “cut” with one or more adulterants was wrongly reported to be caused by legal nicotine vaping.

    According to the report, the EVALI outbreak triggered Bloomberg Philanthropies to invest $160 million over a three year period to prohibit all e-cigarette flavors other than tobacco flavor. EVALI is also still incorrectly referenced by the WHO in its Q&A on vaping products in response to the question as to whether e-cigarettes cause lung injuries.

    However, by early 2020, U.S. authorities identified vitamin E acetate, a cutting agent used in some bootleg THC vaping oils—mainly in US states where cannabis remains illegal—as the primary cause of the outbreak.

    As reported in the dossier and which escaped the attention of the world’s media, last month, 75 global experts with no tobacco industry ties, including seven individuals who have served as president of the Society for Research on Nicotine and Tobacco, wrote to the CDC’s Director asking her to change the name “EVALI” because it fails to alert THC vapers to their potential risks, and it misleads smokers and nicotine vapers to believe e-cigarettes were the cause.

    “I’ve spent 30 years in global health, including three years as a senior advisor on research to the WHO. For most of my career, I worked on HIV, TB, malaria, dengue, rabies, nutrition and child health issues. So, I’ve never seen anything as crazy as what’s happening now in tobacco control. What troubles me is how few people outside of my ‘little’ echo chamber, the community of millions of ex-smokers who use safer nicotine, knows what’s going on,” says Gardner.

    “There are 1.1 billion smokers now in the world, a situation that has barely changed in the last 20 years. The anti-harm reduction conservatism of the WHO and Bloomberg is not working.

    “That’s why we are calling for a global response in the form of a tobacco harm reduction working group and international governments collectively questioning and challenging the WHO and Bloomberg’s prohibitionist and evidence-denialist approach to safer nicotine. Because we are ex-smokers who use safer nicotine. We see what’s happening, and we have great empathy for smokers and ex-smokers who vape.

    “The goal is simple. Save lives. Only the starting assumptions and strategies to get there differ. These can be debated. But this debate is unethical if it does not include people who have, themselves, made the transition from smoking to not-smoking, using tobacco harm reduction products (nicotine patches, nicotine gum & lozenges, nicotine vapes, nicotine pouches, snus and HPTs).”

    “Our future policy recommendations will focus on the need to change research priorities, just as HIV/AIDS activists sought to do in the 1990s. Global tobacco control research priorities today are skewed towards finding harms of alternative nicotine products while ignoring—or not even exploring—benefits, in particular the potential therapeutic benefits of nicotine. The health benefits of medical marijuana are now recognized because of research. The potential therapeutic benefits of psilocybin are now being explored (e.g., for PTST, and even for smoking cessation). However, research to explore those potential benefits was locked in amber for 30 years because of prohibitionist drug laws.”

  • Navajo Tribe Bans Indoor Vaping and Smoking

    Navajo Tribe Bans Indoor Vaping and Smoking

    The president of Navajo Nation has confirmed that vaping e-cigarettes and the use combustible tobacco products will be banned in enclosed public locations within the reservation, including at the tribe’s four casinos. Jonathan Nez, president of the largest Native American Reservation in the United States, signed the legislation on Saturday.

    Jonathan Nez, Credit: Navajo Nation

    The permanent enactment yesterday “is a fundamental right to protect our Navajo people’s right to breathe clean air,” Nez said in a statement. Tobacco use in the tribe’s private homes or for ceremonial purposes will still be allowed, as long as they don’t function as childcare centers, adult care centers, or as business offices, ABC News reported.

    Tribal lawmakers approved the bill in October that prohibits the use of cigarettes, chewing tobacco, electronic cigarettes and other commercial products in public buildings and workspaces, including a 25-foot (7.6-meter) buffer outdoors. Comments submitted to the Navajo Nation Council on the measure overwhelmingly supported it. A few cited the potential of lost revenue for the tribal gambling enterprise that unsuccessfully sought to carve out an exemption from the ban.

    Smoking had been prohibited at the tribe’s four casinos — three in New Mexico and one east of Flagstaff — under COVID-19 safety measures, but it wasn’t permanent until Nez signed the legislation Saturday. The Tribal Council approved a ban on smoking and chewing tobacco in public places in 2008, but then-President Joe Shirley Jr. vetoed it, partially because he was concerned about gambling revenue. An override effort fell short of the votes it needed.

  • Bates: COP9 is ‘Closed Bubbles of Cultivated Groupthink’

    Bates: COP9 is ‘Closed Bubbles of Cultivated Groupthink’

    Credit: Artur

    In a new blog post, tobacco control advocate Clive Bates says that the World Health Organization’s tobacco control treaty meetings are “closed bubbles of cultivated groupthink.” Bates compares the United Nation’s climate change treaty with its tobacco control treaty , claiming the two groups use science and logic in completely different ways.

    “At the start of COP9, the head of the [Framework Convention on Tobacco Control] FCTC convention secretariat proudly drew a comparison with the other COP, the one going on in Glasgow dealing with the UN Framework Convention on Climate Change (UNFCC),” Bates writes. “Perhaps she hoping some of the interest in UNFCCC COP-26 would rub off on the altogether more tawdry FCTC COP-9. But the tobacco COP takes an aggressive exclusionary and insular approach to stakeholders that would never be tolerated in the climate COP.”

    clive bates
    Clive Bates

    There is a sharp contrast between the climate COP meetings and tobacco COP meetings, according to Bates. The FCTC tobacco COP has “highly restrictive and opaque practices” that ensure that it operates as an “echo chamber populated by compliant observers.” He says that the COP9 chooses so-called “civil society” organizations according to their willingness to support the FCTC and contribute to its implementation.

    “It excludes many legitimate perspectives: notably consumers, pro-harm reduction public health experts, policy think tanks and critical economists, libertarians, and commercial entities affected by decisions made by COP,” he says. “For this COP, the FCTC process will be used to exclude several organizations and bolster the groupthink bubble … This insularity is not a feature of the UNFCCC climate COP meetings. A comparison with the UN Framework Convention on Climate Change is revealing.”

    In the FCTC, any non-governmental organization (NGO) can be refused observer status at the request of a single party. NGOs are required to be international and committed to tobacco control, ruling out most consumer organizations who see themselves as victims of tobacco control. NGO observers are required to file reports on their activity with the Secretariat for approval. 

    “The Secretariat then makes recommendations about who should be granted observer status, retained as observers, or expelled,” he says. “The ‘civil society’ organizations chosen are mainly grant-funded tobacco control organizations, often with bizarre views about public health that bear little relationship to the norms in the countries they come from or anything like good practice in policy and science.”